DPCO 2013 and NPPA: Reconciling Scheduled-Drug Overcharging Recovery

A Tier-1 integrated pharma formulator running a scheduled-formulation portfolio of the order of one hundred and eighty formulations across forty-two molecules — anti-infectives, cardiovascular medicines, anti-diabetic medicines, gastroenterology and central nervous system products — closes its books for September 2026 and reviews the National Pharmaceutical Pricing Authority (NPPA) notification calendar for the tax period. Eight molecules in the portfolio have received revised ceiling-price notifications during the quarter under Paragraph 4 of the Drugs (Prices Control) Order 2013 (DPCO 2013). Each notification carries an effective date approximately thirty days from the date of the notification. Within that thirty-day window the formulator must reduce the maximum retail price (MRP) on every scheduled stock keeping unit (SKU) matching the notified molecule-strength-dosage-form combination to at or below the notified ceiling, update the SAP or Oracle price-master, notify distributors through the trade channel, complete physical relabelling or restickering of stock at the depot level, and confirm through retail-audit sampling that the reduced MRP is reflected on the pharmacy shelf. Any residual overcharging on post-effective-date sales — MRP still above the notified ceiling — becomes a Paragraph 20 recovery exposure: principal (overcharged amount per unit multiplied by units sold) plus interest linked to the Wholesale Price Index (WPI), recoverable by the NPPA through a demand notice in Form DPCO-6. This is DPCO 2013 NPPA ceiling price overcharging recovery reconciliation at operating scale, and the discipline that separates a defensible standing compliance posture from a compounding Form DPCO-6 exposure sits in a per-SKU tracker that ingests every NPPA notification, drives the thirty-day-window response workflow, quantifies any residual overcharging as an Ind AS 37 provision, and manages the demand-notice representation cycle to closure.

The reconciliation in one paragraph

A scheduled-formulation portfolio holder sells its output under a molecule-strength-dosage-form combination that is listed on the National List of Essential Medicines 2022 — the First Schedule to DPCO 2013. Under Paragraph 4 of DPCO 2013 the NPPA fixes a ceiling price for each scheduled formulation, computed as the simple average of the prices to retailer of all brands with a one-percent-or-higher market share, rounded to the nearest rupee, plus a sixteen-percent retail margin. Ceilings are revised on a rolling basis — quarterly clusters of notifications for market-share-driven revisions and an annual WPI-linked adjustment cycle. Each notification carries an effective date approximately thirty days after the notification date. Within that window the manufacturer must reduce MRP to at or below the ceiling on every matching SKU. Any residual overcharging feeds the Paragraph 20 recovery exposure — principal plus WPI-linked interest, recovered by the NPPA through a demand notice in Form DPCO-6 with deposit into the Drugs Prices Equalisation Account (DPEA). Under Ind AS 37 (Provisions, Contingent Liabilities and Contingent Assets) the exposure is recognised as a provision when a present obligation exists and a reliable estimate can be made — either on receipt of a Form DPCO-6 demand notice or on the manufacturer’s own identification of post-effective-date sales above the ceiling where the NPPA’s demand-notice practice for similar patterns is well-established. The reconciliation workbook keys on molecule-strength-form, notification date, effective date, notified ceiling, live MRP and variance flag — feeding the thirty-day-window response workflow at one end and the Ind AS 37 provision movement at the other.

What the scenario looks like in India — safe illustrative brand persona

The Indian scheduled-formulation portfolio is concentrated across a small number of Tier-1 and Tier-2 integrated formulators whose therapy-area coverage overlaps materially with the NLEM 2022 basket. Illustrative Tier-1 formulators carrying scheduled-formulation portfolios at the scale relevant to this reconciliation include Sun Pharmaceutical Industries, Dr Reddy’s Laboratories, Cipla, Aurobindo Pharma, Lupin, Zydus Lifesciences (the merged entity formerly Cadila Healthcare), Torrent Pharmaceuticals, Alkem Laboratories, Glenmark Pharmaceuticals and Cadila Pharmaceuticals. Tier-2 formulators with meaningful scheduled-formulation exposure include Ipca Laboratories, Ajanta Pharma, Natco Pharma, JB Chemicals & Pharmaceuticals, and Wockhardt. Speciality and biosimilars formulators with narrower scheduled exposure (concentrated in specific therapy areas rather than a broad NLEM footprint) include Biocon Biologics, Piramal Pharma, Laurus Labs, Granules India and Strides Pharma Science.

For the reconciliation this article walks through, the reference persona is a Tier-1 integrated formulator carrying a scheduled-formulation portfolio of approximately one hundred and eighty formulations across forty-two molecules. Therapy-area mix runs to anti-infectives (approximately twenty-eight molecules — cephalosporin antibiotics, macrolides, fluoroquinolones, anti-tuberculosis fixed-dose combinations), cardiovascular medicines (twelve molecules — atorvastatin, rosuvastatin, telmisartan, amlodipine, losartan), anti-diabetic medicines (eight molecules — metformin, sitagliptin, vildagliptin, glimepiride, empagliflozin), gastroenterology (six molecules — pantoprazole, omeprazole, ranitidine), central nervous system (five molecules — sertraline, escitalopram, olanzapine), and speciality categories including oncology and immunosuppressants (the remaining approximately eleven molecules across the portfolio). Each molecule appears in the portfolio across multiple strengths (for example atorvastatin 10 mg, 20 mg and 40 mg) and dosage forms (tablet, capsule, syrup, injectable), producing the total SKU count of approximately one hundred and eighty scheduled formulations. The persona’s manufacturing footprint is multi-plant — Ahmedabad, Vadodara, Sikkim, Baddi — with each plant carrying a subset of the scheduled-formulation SKU list. The corporate indirect-tax-and-pricing function centrally monitors the NPPA notification calendar and drives the standing compliance workflow across the plant network.

The regulatory overlay — DPCO 2013, NPPA, NLEM 2022 and the Paragraph 20 recovery mechanism

Four anchors govern the scheduled-formulation portfolio holder’s DPCO-NPPA reconciliation cycle. Each is procedural in its own field but interlocks with the others through the ceiling-price notification and the Paragraph 20 recovery lifecycle.

The Drugs (Prices Control) Order 2013 was notified by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, under Section 3 of the Essential Commodities Act 1955 — the enabling statute that empowers the Central Government to regulate the production, supply, distribution and price of essential commodities. The classification of drugs as an essential commodity was retained on the Schedule to the Essential Commodities Act by successive notifications and stands as the constitutional-validity anchor for the NPPA’s ceiling-price-fixation authority. DPCO 2013 replaced the earlier DPCO 1995 regime and introduced the market-based ceiling-price formula in place of the earlier cost-based formula.

The National Pharmaceutical Pricing Authority is the statutory body constituted by the Government of India in 1997 that exercises the ceiling-price-fixation and enforcement authority under DPCO 2013. The NPPA operates from New Delhi and publishes ceiling-price notifications, trade-margin-rationalisation orders, Form DPCO-6 demand notices and monitoring circulars on the NPPA portal at nppaindia.nic.in. Its authority extends across ceiling-price fixation for scheduled formulations under Paragraph 4, the ten-percent-per-year price-increase cap monitoring for non-scheduled formulations under Paragraph 20, trade-margin-rationalisation on selected non-scheduled medical devices under Paragraph 19 (cardiac stents at bare-metal Rs 8,261 and drug-eluting Rs 9,285 per unit under the 2017 and subsequent revised notifications; orthopaedic knee implants across a range of approximately Rs 54,720 to Rs 113,950 depending on category under the 2017 order), and overcharging recovery through Form DPCO-6 demand notices with deposit into the Drugs Prices Equalisation Account (DPEA).

The National List of Essential Medicines 2022 was published by the Ministry of Health and Family Welfare in September 2022. It lists approximately three hundred and eighty-four medicines across therapeutic categories including anti-infectives, cardiovascular medicines, anti-diabetic medicines, oncology, immunosuppressants and psychotropic medicines. The formulations of medicines on NLEM 2022 constitute the First Schedule to DPCO 2013 — meaning ceiling-price fixation by the NPPA under Paragraph 4 applies to these formulations. The 2022 revision from NLEM 2015 added new medicines (including several oncology and anti-diabetic agents) and removed obsolete ones, and the corresponding ceiling-price recalculation cycle ran across 2022 and 2023 NPPA notifications.

Paragraph 4 of DPCO 2013 gives the ceiling-price formula. Ceiling price of a scheduled formulation equals the simple average of the prices to retailer of all brands of the formulation with a market share of one percent or more of the total market turnover for that formulation, rounded to the nearest rupee, plus a sixteen-percent retail margin computed on that average. Market share is computed on the basis of moving annual turnover (MAT) data typically sourced from IQVIA (formerly IMS Health) or All Indian Origin Chemists and Distributors (AIOCD) AWACS databases. The ceiling price is the MRP inclusive of all taxes and margins that any manufacturer may charge for that formulation. The ceiling is revised annually on the anniversary of the notification date, adjusted by the WPI year-on-year percentage change for the preceding calendar year, and is also revised on market-share basis when the NPPA re-runs the Paragraph 4 computation.

Paragraph 20 of DPCO 2013 governs the recovery mechanism. Paragraph 20(1) provides that no manufacturer of a non-scheduled formulation shall increase the MRP by more than ten percent during any preceding twelve-month period. Paragraph 20(2) empowers the Central Government (acting through the NPPA) to direct any manufacturer to deposit the overcharged amount — the excess of the MRP charged over the price permitted under Paragraph 20(1) or, in the case of a scheduled formulation, over the ceiling price notified under Paragraph 4 — along with interest at the rate of the Wholesale Price Index for the relevant period, into the DPEA. Recovery is effected through a demand notice in Form DPCO-6. The manufacturer may file a representation or seek review under Paragraph 20(3) within the timeline specified in the notice. Non-payment attracts further recovery proceedings under Sections 7 and 8 of the Essential Commodities Act 1955.

A worked example — an illustrative September 2026 notification cycle

Illustrative — the following figures represent the operating pattern of a Tier-1 pharma formulator carrying a scheduled-formulation portfolio at the scale that Indian large-cap listed formulators operate. Public disclosures do not reveal per-SKU overcharging quantum in the granularity below; cross-verify against your own SKU tracker, live NPPA notifications and internal retail-audit data before action.

For the September 2026 quarterly notification cycle the NPPA publishes revised ceiling-price notifications on eight molecules relevant to the formulator’s portfolio. Six of the eight are market-share-driven downward revisions (the average price-to-retailer across the top brands has moved down since the previous computation, pulling the ceiling down); two are annual WPI-linked upward adjustments. The portfolio impact table:

The six downward revisions carry the compliance workload — the two upward WPI revisions are permissive (the formulator may increase MRP to the new ceiling but is not obliged to). For each downward revision the workflow triggers on the notification date: the SAP or Oracle price-master change to reduce the SKU MRP to at or below the new ceiling by the effective date; the trade-notification to distributors carrying the pricing change and the effective date; the depot-level physical relabelling or restickering of packed stock; the retail-audit sampling schedule to verify shelf-level MRP compliance within a week of the effective date.

Assume that on the atorvastatin 10 mg tablet SKU (three brands of the formulator’s portfolio) the SAP price-master change is executed on 12 October 2026 (three days before the 15 October effective date), the trade notification is issued on the same day, depot restickering completes across the plant network by 14 October, and the retail-audit sampling on 22 October confirms shelf-level MRP compliance in a majority of the sampled outlets. However, the retail-audit surfaces that in twelve percent of sampled outlets the pre-relabelled stock is still on the shelf and being sold at the old MRP of Rs 82, three rupees above the new ceiling of Rs 74 (post the sixteen-percent margin arithmetic, the effective overcharging per strip is Rs 3 not Rs 8, because the ceiling and MRP arithmetic is at the same margin level). Over the seven days from the effective date (15 October) to the audit date (22 October), the estimated units sold at the higher MRP across the affected outlets is approximately eighteen thousand strips.

Paragraph 20 overcharging exposure computation for the atorvastatin 10 mg SKU: principal = 18,000 strips × Rs 3 per strip = Rs 54,000 (illustrative). WPI-linked interest at an illustrative WPI rate of 3.5 percent applied over the exposure period (approximately half a month, or one-twenty-fourth of a year) = Rs 79 (illustrative). Total exposure = Rs 54,079 — a small individual line but one of dozens of similar lines across the eight-molecule notification cycle, and one of hundreds across a full-year notification cadence.

The Ind AS 37 recognition test: the past event (post-effective-date sales above the ceiling) has occurred; the present obligation is created by DPCO 2013 Paragraph 20(2) read with the NPPA’s well-established Form DPCO-6 demand-notice practice; a reliable estimate can be made from the retail-audit data. A provision is recognised at Rs 54,079 for the atorvastatin 10 mg exposure line — aggregated with all similar lines across the portfolio into the consolidated Ind AS 37 provision balance. If the Form DPCO-6 demand notice is subsequently received at Rs 54,000 principal plus Rs 79 interest, the provision is utilised. If a representation under Paragraph 20(3) succeeds in reducing the demand, the provision is released to the extent of the reduction.

Common reconciliation breakages

Four breakages recur across Indian scheduled-formulation portfolio holders running the DPCO-NPPA reconciliation cycle, and each maps to a specific control failure that a Form DPCO-6 demand notice — or an auditor’s Ind AS 37 review — will surface.

• Thirty-day-window slippage on physical relabelling. The SAP or Oracle price-master change is a same-day update; the trade-notification to distributors is a same-week task; the physical relabelling or restickering of packed stock at the depot level is a multi-week operational job. Formulators that treat the SAP change as compliance-complete without tracking the depot-level restickering across the full plant network produce a compliance gap in the ten-to-fourteen days after the effective date, during which pre-relabelled stock continues to be dispatched to distributors and sold at the old MRP. The Paragraph 20 exposure crystallises across the gap. Reconciliation discipline: the thirty-day-window response workflow includes an explicit depot-level restickering sub-status per SKU per plant, with the retail-audit sub-status closing the loop only after shelf-level MRP is confirmed.

• Molecule-strength-form mismatch with the NPPA notification. The NPPA notification is precise on molecule, strength and dosage form (for example atorvastatin 10 mg tablet — not atorvastatin 20 mg tablet, not atorvastatin 10 mg orodispersible tablet, not atorvastatin 10 mg extended-release tablet). Formulators whose SKU master carries loose molecule tagging without strength and form granularity produce false-positive matches (SKUs flagged as covered by the notification but actually not) or false-negative matches (SKUs that are covered but not flagged). The reconciliation error catalogue documents the failure family that this belongs to. Reconciliation discipline: the SKU master carries molecule-strength-form as a composite key with an explicit NLEM 2022 First Schedule match, so the notification-to-SKU matching is deterministic.

• Ind AS 37 recognition-versus-disclosure misclassification. The recognition test under Ind AS 37 paragraph 14 requires a present obligation, probable outflow and a reliable estimate. Formulators that recognise a provision for every retail-audit-identified overcharging line — regardless of the strength of the NPPA demand-notice pattern for that fact set — over-provision the balance sheet. Conversely, formulators that treat every overcharging line as a contingent liability disclosed under paragraph 86 — waiting for the Form DPCO-6 demand notice to arrive before recognising — under-provision. The correct discipline is a two-tier classification: exposure lines where the NPPA’s Form DPCO-6 demand-notice practice for similar fact sets is well-established are provisioned; exposure lines where the fact pattern is disputed (SKU-to-notification match, market-share basis of the ceiling itself) are disclosed as contingent liabilities. The reconciliation failure mode analysis pillar and the reconciliation playbook for monthly close both walk the recognition-versus-disclosure decision tree in more detail.

• WPI-linked interest computation errors on Form DPCO-6 response. The Paragraph 20(2) recovery mechanism specifies interest at the Wholesale Price Index rate for the relevant period. The WPI series is published monthly by the Office of the Economic Adviser, Ministry of Commerce and Industry, and the applicable rate for a Form DPCO-6 exposure line is the WPI for the exposure period. Formulators that apply a flat interest rate (for example a bank base rate or the RBI repo rate) to the internal provision computation produce a variance against the NPPA’s own Form DPCO-6 interest computation — leading to under-provisioning if the actual WPI-linked interest is higher, or an unnecessary representation cycle if the internal computation is materially higher than the demand notice’s own figure. Reconciliation discipline: the internal WPI-linked interest computation follows the same methodology and same underlying WPI series that the NPPA uses in its Form DPCO-6 issuance.

How a reconciliation platform handles this

A purpose-built pharma reconciliation platform ingests the scheduled-formulation SKU master with molecule-strength-form as a composite key anchored to the NLEM 2022 First Schedule, monitors the NPPA portal for new ceiling-price notifications on a daily basis, matches every notification to the impacted SKUs deterministically, triggers the thirty-day-window response workflow across the SAP or Oracle price-master change, the trade-notification, the depot-level restickering across the plant network, and the retail-audit sub-status, quantifies any residual post-effective-date overcharging as principal-plus-WPI-linked-interest, drives the Ind AS 37 recognition-versus-disclosure classification, and manages the Form DPCO-6 demand-notice representation cycle to closure. Match rate improvement of 51 to 88 percent on the SKU-master-to-NPPA-notification reconciliation, combined with an ISO 27001:2022 posture and DPDP Act 2023 aligned data handling, is what makes the platform an infrastructure investment for a Tier-1 pharma formulator running a scheduled-formulation portfolio at scale rather than a spreadsheet substitute.

Cross-cluster bridges and where to read next

The DPCO-NPPA reconciliation cycle documented in this article sits alongside the broader indirect-tax and incentive-scheme reconciliation surfaces that a scheduled-formulation portfolio holder runs in parallel. The PLI Pharma Rs 15,000 crore scheme eligibility and incremental-sales reconciliation walkthrough covers the Production Linked Incentive scheme for pharma, which sits on the same integrated formulator’s finance-team desk as the DPCO-NPPA cycle. The Section 115BAA versus PLI pharma concessional-rate election analysis covers the corporate-tax interplay that a PLI-participating formulator must resolve. The GST Council 56 pharma drugs and medical devices 5 percent transition walkthrough covers the September 2025 rate reset that materially deepened the inversion cycle for the same Chapter 30 formulator population that carries scheduled-formulation exposure. The Rule 89(5) for pharma formulations complete refund playbook is the direct companion piece for the inverted-duty refund cycle that runs monthly alongside the DPCO monitoring cycle.

The methodology framework for building the per-SKU tracker, the thirty-day-window response workflow and the Ind AS 37 recognition-versus-disclosure decision tree sits in Terra Insight’s own reconciliation failure mode analysis pillar and the reconciliation playbook for monthly close operations pillar. The reconciliation error catalogue documents the failure families that a scheduled-formulation SKU-to-NPPA-notification matching process is exposed to. The commercial pillar for the pharma sub-cluster is Pharma reconciliation software India; the broader authority for the platform is reconciliation software India with the pharma cluster hub as the sub-cluster index.

The five FAQs below address the operational questions Indian pharma indirect-tax leads, corporate-pricing controllers and Ind AS 37 auditors ask most often when reviewing the standing DPCO-NPPA compliance posture for a scheduled-formulation portfolio.

Terra Insight Editorial Team Reconciliation Infrastructure

Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →

Published 17 July 2026

Domain expertise

TDS Reconciliation GST Input Credit Platform Settlements NACH Batch Matching Bank Reconciliation Form 26AS Matching ERP Integrations Enterprise Finance Ops

Reviewed by

NK

Navin Krishnan

Managing Director & Founder — Terra Insight

Ex Amazon India · Intuit QuickBooks · Tata nexarc

ISO 27001:2022 Patent Pending Incorporated 2024